{"id":2239,"date":"2022-02-02T00:00:00","date_gmt":"2022-02-02T00:00:00","guid":{"rendered":"http:\/\/centogene.vl22350.dinaserver.com\/2239"},"modified":"2022-02-02T00:00:00","modified_gmt":"2022-02-02T00:00:00","slug":"centogene-announces-usd-62-million-aggregate-equity-and-debt-financings-to-support-growth-plan","status":"publish","type":"post","link":"https:\/\/www.centogene.com\/pl\/centogene-announces-usd-62-million-aggregate-equity-and-debt-financings-to-support-growth-plan\/","title":{"rendered":"CENTOGENE og\u0142asza \u0142\u0105czn\u0105 kwot\u0119 62 milion\u00f3w dolar\u00f3w ameryka\u0144skich w postaci finansowania kapita\u0142owego i d\u0142u\u017cnego w celu wsparcia planu rozwoju"},"content":{"rendered":"<ul>\n<li>Enables refocusing on core business of delivering valuable, data-driven insights to patients, and pharmaceutical companies globally<\/li>\n<li>EUR 15 million private placement from leading growth investors and a USD 45 million senior secured loan from Oxford Finance to fortify CENTOGENE\u2019s balance sheet<\/li>\n<li>Financings significantly enhance opportunity for significant value creation as the unique and essential partner for patients, physicians, and biopharma in rare, metabolic, and neurodegenerative diseases<\/li>\n<\/ul>\n<p> CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, February 1, 2022 (GLOBE NEWSWIRE \u2013 Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced the closing of a EUR 15 million (approx. USD 17 million) private placement financing from investors led by DPE Deutsche Private Equity, TVM Capital Life Science, and Careventures (the \u201cPrivate Placement Financing\u201d), as well as the entry into a USD 45 million senior secured loan facility provided by Oxford Finance LLC, a specialty finance firm providing senior debt to life sciences and healthcare companies (the \u201cLoan Facility\u201d).<\/p>\n<p>\u201cWe are very pleased to report today that we have secured a strong financial foundation for CENTOGENE, which will fuel our advancement on our path towards significant value creation,\u201d said Kim Stratton, Chief Executive Officer of CENTOGENE. \u201cWe are now looking forward to expeditiously delivering on the promise of strong growth in our core business in 2022 and strengthening CENTOGENE\u2019s position as the unique and essential partner for patients, physicians, and biopharma in rare, metabolic, and neurodegenerative diseases.\u201d<\/p>\n<p>\u201cThis significant capital infusion will not only strengthen our balance sheet, but also allow us to accelerate growth and innovation and to deliver on some exciting, future value inflection milestones as outlined in our strategic plan,\u201d said Ren\u00e9 Just, CENTOGENE\u2019s Chief Financial Officer. \u201cThis financing is the result of CENTOGENE management\u2019s and its Supervisory Board\u2019s comprehensive review of a wider range of financial and strategic options. Having taken all aspects into consideration and diligently addressing the financing need, we are convinced this solution maximizes the value to our stakeholders. Additionally, the debt financing minimizes dilution to our shareholders and the dual tranche structure increases our financial flexibility.\u201d<\/p>\n<p>\u201cCENTOGENE has built a strong position in the field of rare, metabolic, and neurodegenerative diseases by providing precise medical diagnosis at the earliest possible moment,\u201d said Christopher A. Herr, Senior Managing Director at Oxford Finance. \u201cThrough this partnership, the Company is positioned to continue generating leading edge medical insights and broaden its set of biopharma and pharmaceutical partners globally.\u201d<\/p>\n<h4>Terms of the Financings<\/h4>\n<p>The Private Placement Financing includes the sale of 4,479,088 shares of common stock at a price per share of USD 3.73 and warrants to acquire up to 1,343,727 additional shares of common stock at an exercise price per share of USD 7.72. Under the terms of the Loan Facility, CENTOGENE has drawn down USD 25 million and will have access to a second tranche of USD 20 million upon the achievement of certain conditions.<\/p>\n<p>Moelis &amp; Company served as CENTOGENE\u2019s financial advisor in connection with the financings.<\/p>\n<h4>About Oxford Finance LLC<\/h4>\n<p>Oxford Finance is a specialty finance firm providing senior secured loans to public and private life sciences and healthcare services companies worldwide. For over 20 years, Oxford has delivered flexible financing solutions to its clients, enabling these companies to maximize their equity by leveraging their assets. In recent years, Oxford has originated over $8.5 billion in loans, with lines of credit ranging from $5 million to $200 million. Oxford is headquartered in Alexandria, Va., with additional offices in San Diego, Calif.; Palo Alto, Calif.; and the greater Boston and New York City areas. For more information, visit <a href=\"https:\/\/oxfordfinance.com\/\" target=\"_blank\" title=\"Visit OXFORD FINANCE\">https:\/\/oxfordfinance.com\/<\/a><\/p>\n<h4>O firmie CENTOGENE<\/h4>\n<p>CENTOGENE zajmuje si\u0119 diagnostyk\u0105 i badaniami nad chorobami rzadkimi, przekszta\u0142caj\u0105c rzeczywiste dane kliniczne, genetyczne i multiomiczne w celu diagnozowania, zrozumienia i leczenia chor\u00f3b rzadkich. Naszym celem jest racjonalizacja decyzji terapeutycznych i przyspieszenie rozwoju nowych lek\u00f3w sierocych poprzez wykorzystanie naszej rozleg\u0142ej wiedzy i danych na temat chor\u00f3b rzadkich. CENTOGENE opracowa\u0142o globaln\u0105, autorsk\u0105 platform\u0119 bada\u0144 nad chorobami rzadkimi, opart\u0105 na naszym repozytorium danych dotycz\u0105cych ponad 600 000 pacjent\u00f3w z ponad 120 kraj\u00f3w.<\/p>\n<p>Platforma firmy obejmuje dane epidemiologiczne, fenotypowe i genetyczne, kt\u00f3re odzwierciedlaj\u0105 globaln\u0105 populacj\u0119, a tak\u017ce biobank pr\u00f3bek krwi pacjent\u00f3w i kultur kom\u00f3rkowych. CENTOGENE uwa\u017ca, \u017ce jest to jedyna platforma skoncentrowana na kompleksowej analizie danych wielopoziomowych w celu lepszego zrozumienia rzadkich chor\u00f3b dziedzicznych. Umo\u017cliwia ona lepsz\u0105 identyfikacj\u0119 i stratyfikacj\u0119 pacjent\u00f3w oraz ich chor\u00f3b podstawowych, co umo\u017cliwia i przyspiesza odkrywanie, rozw\u00f3j i dost\u0119p do lek\u00f3w sierocych. Na dzie\u0144 31 grudnia 2020 r. firma wsp\u00f3\u0142pracowa\u0142a z ponad 30 partnerami farmaceutycznymi.<\/p>\n<p>Obserwuj nas na <a href=\"https:\/\/de.linkedin.com\/company\/centogene\" target=\"_blank\" title=\"Link do LinkedIn\">LinkedIn<\/a><\/p>\n<h4>No Offer or Solicitation<\/h4>\n<p>This press release shall not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The securities sold pursuant to the Private Placement Financing have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the U.S. except pursuant to an effective registration statement or an applicable exemption from the registration requirements.<\/p>\n<h4>O\u015bwiadczenia prognostyczne<\/h4>\n<p>Niniejsza informacja prasowa zawiera \u201co\u015bwiadczenia prognostyczne\u201d w rozumieniu federalnych przepis\u00f3w dotycz\u0105cych papier\u00f3w warto\u015bciowych w Stanach Zjednoczonych. Zawarte w niej o\u015bwiadczenia, kt\u00f3re nie maj\u0105 jednoznacznie historycznego charakteru, maj\u0105 charakter prognostyczny, a s\u0142owa \u201cprzewidywa\u0107\u201d, \u201cwierzy\u0107\u201d, \u201ckontynuowa\u0107\u201d, \u201coczekiwa\u0107\u201d, \u201cszacowa\u0107\u201d, \u201czamierza\u0107\u201d, \u201cprognozowa\u0107\u201d oraz podobne wyra\u017cenia i czasowniki w czasie przysz\u0142ym lub warunkowym, takie jak \u201cb\u0119dzie\u201d, \u201cby\u0142by\u201d, \u201cpowinien\u201d, \u201cm\u00f3g\u0142by\u201d, \u201cmo\u017ce\u201d, \u201cmo\u017ce\u201d i \u201cmo\u017ce\u201d, maj\u0105 na celu identyfikacj\u0119 o\u015bwiadcze\u0144 prognostycznych. Takie o\u015bwiadczenia prognostyczne wi\u0105\u017c\u0105 si\u0119 ze znanymi i nieznanymi ryzykami, niepewno\u015bciami i innymi istotnymi czynnikami, kt\u00f3re mog\u0105 spowodowa\u0107, \u017ce rzeczywiste wyniki, efektywno\u015b\u0107 lub osi\u0105gni\u0119cia CENTOGENE b\u0119d\u0105 istotnie r\u00f3\u017cni\u0107 si\u0119 od jakichkolwiek przysz\u0142ych wynik\u00f3w, efektywno\u015bci lub osi\u0105gni\u0119\u0107 wyra\u017conych lub dorozumianych w o\u015bwiadczeniach prognostycznych. Takie ryzyka i niepewno\u015bci obejmuj\u0105 mi\u0119dzy innymi negatywne warunki gospodarcze na ca\u0142ym \u015bwiecie oraz ci\u0105g\u0142\u0105 niestabilno\u015b\u0107 i zmienno\u015b\u0107 na \u015bwiatowych rynkach finansowych, wp\u0142yw pandemii COVID-19 na nasz\u0105 dzia\u0142alno\u015b\u0107 i wyniki operacyjne, mo\u017cliwe zmiany w obowi\u0105zuj\u0105cych i proponowanych przepisach, regulacjach i politykach rz\u0105dowych, presj\u0119 wynikaj\u0105c\u0105 ze wzrostu konkurencji i konsolidacji w naszej bran\u017cy, koszty i niepewno\u015b\u0107 zwi\u0105zan\u0105 z zatwierdzeniem regulacyjnym, w tym przez Ameryka\u0144sk\u0105 Agencj\u0119 ds. \u017bywno\u015bci i Lek\u00f3w, nasze uzale\u017cnienie od stron trzecich i partner\u00f3w, w tym nasz\u0105 zdolno\u015b\u0107 do zarz\u0105dzania wzrostem i nawi\u0105zywania nowych relacji z klientami, nasz\u0105 zale\u017cno\u015b\u0107 od bran\u017cy chor\u00f3b rzadkich, nasz\u0105 zdolno\u015b\u0107 do zarz\u0105dzania ekspansj\u0105 mi\u0119dzynarodow\u0105, nasz\u0105 zale\u017cno\u015b\u0107 od kluczowego personelu, nasz\u0105 zale\u017cno\u015b\u0107 od ochrony w\u0142asno\u015bci intelektualnej, wahania naszych wynik\u00f3w operacyjnych spowodowane wp\u0142ywem kurs\u00f3w walutowych, nasz\u0105 zdolno\u015b\u0107 do usprawnienia wykorzystania got\u00f3wki, nasze zapotrzebowanie na dodatkowe finansowanie i nasz\u0105 zdolno\u015b\u0107 do kontynuowania dzia\u0142alno\u015bci lub inne czynniki. Aby uzyska\u0107 wi\u0119cej informacji na temat ryzyka i niepewno\u015bci, kt\u00f3re mog\u0105 spowodowa\u0107, \u017ce rzeczywiste wyniki b\u0119d\u0105 si\u0119 r\u00f3\u017cni\u0107 od tych wyra\u017conych w niniejszych o\u015bwiadczeniach prognostycznych, a tak\u017ce ryzyka zwi\u0105zanego z dzia\u0142alno\u015bci\u0105 CENTOGENE og\u00f3lnie, zapoznaj si\u0119 z czynnikami ryzyka CENTOGENE przedstawionymi w formularzu 20-F z\u0142o\u017conym przez CENTOGENE 15 kwietnia 2021 r. w Komisji Papier\u00f3w Warto\u015bciowych i Gie\u0142d (SEC) oraz w p\u00f3\u017aniejszych dokumentach z\u0142o\u017conych w SEC. Wszelkie o\u015bwiadczenia prognostyczne zawarte w niniejszym komunikacie prasowym obowi\u0105zuj\u0105 wy\u0142\u0105cznie na dzie\u0144 jego sporz\u0105dzenia, a CENTOGENE wyra\u017anie zrzeka si\u0119 obowi\u0105zku aktualizacji jakichkolwiek o\u015bwiadcze\u0144 prognostycznych, niezale\u017cnie od tego, czy wynika to z nowych informacji, przysz\u0142ych zdarze\u0144, czy z innych przyczyn.<\/p>\n<h5>Kontakt dla medi\u00f3w: &nbsp;<\/h5>\n<p>CENTOGENE<br \/> Ben Legg<br \/> Komunikacja korporacyjna&nbsp;<br \/> <a href=\"mailto:press@centogene.com\" title=\"Napisz e-mail\">press(at)centogene(dot)com<\/a><\/p>\n<p>Lennart Streibel<br \/> Relacje inwestorskie<br \/> <a href=\"mailto:investor.relations@centogene.com\u00a0\" title=\"Napisz e-mail\">investor.relations(at)centogene(dot)com&nbsp;<\/a><\/p>\n<p>Stern IR &nbsp;<br \/> Brendan Payne<br \/> +1 (212) 698 8695<br \/> <a href=\"mailto:brendan.payne@sternir.com\" title=\"Napisz e-mail\">brendan.payne(at)sternir(dot)com<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Enables refocusing on core business of delivering valuable, data-driven insights to patients, and pharmaceutical companies globally EUR 15 million private [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2239","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CENTOGENE Announces USD 62 Million Aggregate Equity and Debt Financings to Support Growth Plan | CENTOGENE<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.centogene.com\/pl\/centogene-announces-usd-62-million-aggregate-equity-and-debt-financings-to-support-growth-plan\/\" \/>\n<meta property=\"og:locale\" content=\"pl_PL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CENTOGENE Announces USD 62 Million Aggregate Equity and Debt Financings to Support Growth Plan | CENTOGENE\" \/>\n<meta property=\"og:description\" content=\"Enables refocusing on core business of delivering valuable, data-driven insights to patients, and pharmaceutical companies globally EUR 15 million private [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.centogene.com\/pl\/centogene-announces-usd-62-million-aggregate-equity-and-debt-financings-to-support-growth-plan\/\" \/>\n<meta property=\"og:site_name\" content=\"CENTOGENE\" \/>\n<meta property=\"article:published_time\" content=\"2022-02-02T00:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.centogene.com\/wp-content\/uploads\/2025\/03\/csm_centogene-diagnostics-priority-disease-03_5a57c07603.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"740\" \/>\n\t<meta property=\"og:image:height\" content=\"416\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"admincg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Napisane przez\" \/>\n\t<meta name=\"twitter:data1\" content=\"admincg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Szacowany czas czytania\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-usd-62-million-aggregate-equity-and-debt-financings-to-support-growth-plan\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-usd-62-million-aggregate-equity-and-debt-financings-to-support-growth-plan\\\/\"},\"author\":{\"name\":\"admincg\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/person\\\/d9b8738539a9ddb5de5a02a909d40b8b\"},\"headline\":\"CENTOGENE Announces USD 62 Million Aggregate Equity and Debt Financings to Support Growth Plan\",\"datePublished\":\"2022-02-02T00:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-usd-62-million-aggregate-equity-and-debt-financings-to-support-growth-plan\\\/\"},\"wordCount\":1266,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\"},\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"pl-PL\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-usd-62-million-aggregate-equity-and-debt-financings-to-support-growth-plan\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-usd-62-million-aggregate-equity-and-debt-financings-to-support-growth-plan\\\/\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-usd-62-million-aggregate-equity-and-debt-financings-to-support-growth-plan\\\/\",\"name\":\"CENTOGENE Announces USD 62 Million Aggregate Equity and Debt Financings to Support Growth Plan | CENTOGENE\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#website\"},\"datePublished\":\"2022-02-02T00:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-usd-62-million-aggregate-equity-and-debt-financings-to-support-growth-plan\\\/#breadcrumb\"},\"inLanguage\":\"pl-PL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-usd-62-million-aggregate-equity-and-debt-financings-to-support-growth-plan\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-usd-62-million-aggregate-equity-and-debt-financings-to-support-growth-plan\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.centogene.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CENTOGENE Announces USD 62 Million Aggregate Equity and Debt Financings to Support Growth Plan\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#website\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/\",\"name\":\"CENTOGENE\",\"description\":\"Guiding Precision Medicine\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.centogene.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pl-PL\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\",\"name\":\"CENTOGENE\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pl-PL\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/CENTOGENE-Flower.png\",\"contentUrl\":\"https:\\\/\\\/www.centogene.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/CENTOGENE-Flower.png\",\"width\":246,\"height\":246,\"caption\":\"CENTOGENE\"},\"image\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/centogene\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UClZxtN_laC1_ZtCdxkasdPQ\",\"https:\\\/\\\/www.instagram.com\\\/_centogene_\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/person\\\/d9b8738539a9ddb5de5a02a909d40b8b\",\"name\":\"admincg\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/pl\\\/author\\\/admincg\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CENTOGENE Announces USD 62 Million Aggregate Equity and Debt Financings to Support Growth Plan | CENTOGENE","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.centogene.com\/pl\/centogene-announces-usd-62-million-aggregate-equity-and-debt-financings-to-support-growth-plan\/","og_locale":"pl_PL","og_type":"article","og_title":"CENTOGENE Announces USD 62 Million Aggregate Equity and Debt Financings to Support Growth Plan | CENTOGENE","og_description":"Enables refocusing on core business of delivering valuable, data-driven insights to patients, and pharmaceutical companies globally EUR 15 million private [&hellip;]","og_url":"https:\/\/www.centogene.com\/pl\/centogene-announces-usd-62-million-aggregate-equity-and-debt-financings-to-support-growth-plan\/","og_site_name":"CENTOGENE","article_published_time":"2022-02-02T00:00:00+00:00","og_image":[{"width":740,"height":416,"url":"https:\/\/www.centogene.com\/wp-content\/uploads\/2025\/03\/csm_centogene-diagnostics-priority-disease-03_5a57c07603.webp","type":"image\/webp"}],"author":"admincg","twitter_card":"summary_large_image","twitter_misc":{"Napisane przez":"admincg","Szacowany czas czytania":"6 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.centogene.com\/centogene-announces-usd-62-million-aggregate-equity-and-debt-financings-to-support-growth-plan\/#article","isPartOf":{"@id":"https:\/\/www.centogene.com\/centogene-announces-usd-62-million-aggregate-equity-and-debt-financings-to-support-growth-plan\/"},"author":{"name":"admincg","@id":"https:\/\/www.centogene.com\/#\/schema\/person\/d9b8738539a9ddb5de5a02a909d40b8b"},"headline":"CENTOGENE Announces USD 62 Million Aggregate Equity and Debt Financings to Support Growth Plan","datePublished":"2022-02-02T00:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.centogene.com\/centogene-announces-usd-62-million-aggregate-equity-and-debt-financings-to-support-growth-plan\/"},"wordCount":1266,"commentCount":0,"publisher":{"@id":"https:\/\/www.centogene.com\/#organization"},"articleSection":["Uncategorized"],"inLanguage":"pl-PL","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.centogene.com\/centogene-announces-usd-62-million-aggregate-equity-and-debt-financings-to-support-growth-plan\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.centogene.com\/centogene-announces-usd-62-million-aggregate-equity-and-debt-financings-to-support-growth-plan\/","url":"https:\/\/www.centogene.com\/centogene-announces-usd-62-million-aggregate-equity-and-debt-financings-to-support-growth-plan\/","name":"CENTOGENE Announces USD 62 Million Aggregate Equity and Debt Financings to Support Growth Plan | CENTOGENE","isPartOf":{"@id":"https:\/\/www.centogene.com\/#website"},"datePublished":"2022-02-02T00:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.centogene.com\/centogene-announces-usd-62-million-aggregate-equity-and-debt-financings-to-support-growth-plan\/#breadcrumb"},"inLanguage":"pl-PL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.centogene.com\/centogene-announces-usd-62-million-aggregate-equity-and-debt-financings-to-support-growth-plan\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.centogene.com\/centogene-announces-usd-62-million-aggregate-equity-and-debt-financings-to-support-growth-plan\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.centogene.com\/"},{"@type":"ListItem","position":2,"name":"CENTOGENE Announces USD 62 Million Aggregate Equity and Debt Financings to Support Growth Plan"}]},{"@type":"WebSite","@id":"https:\/\/www.centogene.com\/#website","url":"https:\/\/www.centogene.com\/","name":"CENTOGENE","description":"Kierowanie medycyn\u0105 precyzyjn\u0105","publisher":{"@id":"https:\/\/www.centogene.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.centogene.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pl-PL"},{"@type":"Organization","@id":"https:\/\/www.centogene.com\/#organization","name":"CENTOGENE","url":"https:\/\/www.centogene.com\/","logo":{"@type":"ImageObject","inLanguage":"pl-PL","@id":"https:\/\/www.centogene.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.centogene.com\/wp-content\/uploads\/2026\/04\/CENTOGENE-Flower.png","contentUrl":"https:\/\/www.centogene.com\/wp-content\/uploads\/2026\/04\/CENTOGENE-Flower.png","width":246,"height":246,"caption":"CENTOGENE"},"image":{"@id":"https:\/\/www.centogene.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/centogene","https:\/\/www.youtube.com\/channel\/UClZxtN_laC1_ZtCdxkasdPQ","https:\/\/www.instagram.com\/_centogene_\/"]},{"@type":"Person","@id":"https:\/\/www.centogene.com\/#\/schema\/person\/d9b8738539a9ddb5de5a02a909d40b8b","name":"admincg","url":"https:\/\/www.centogene.com\/pl\/author\/admincg\/"}]}},"_links":{"self":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/posts\/2239","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/comments?post=2239"}],"version-history":[{"count":0,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/posts\/2239\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/media?parent=2239"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/categories?post=2239"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/tags?post=2239"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}